Benn Bluestein-Veyra
M.Sc. Organic Chemistry · Founder & CEO, ExaVeyra Sciences · Miami, FL
Benn Bluestein-Veyra is the founder and CEO of ExaVeyra Sciences, a Miami-based B2B wholesale supplier of cGMP-grade exosomes, bioactive peptides, and regenerative medical devices for licensed clinics nationwide. He holds an M.Sc. in Organic Chemistry from Universidad Autonoma de Madrid, where his doctoral thesis focused on cobalt-catalyzed C-H functionalization of N-benzylpicolinamide with aliphatic 1,3-diynes. Prior to founding ExaVeyra, he worked as a nucleotide process organic chemist and analytical chemist in next-generation DNA sequencing, developing expertise in large-scale synthetic chemistry, chromatographic purification, and analytical validation.
M.Sc. Organic Chemistry
2019Universidad Autonoma de Madrid
Thesis: Cobalt-catalyzed C-H functionalization of N-benzylpicolinamide with aliphatic 1,3-diynes
Nucleotide Process Organic Chemist
Post-GraduateNext-Generation DNA Sequencing Industry
Large-scale nucleotide synthesis, chromatographic purification, analytical validation for sequencing reagents
B2B Regenerative Medicine Supply Chain
2024ExaVeyra Sciences (Founded)
Molecular-level verification of exosome purity, peptide formulations, and cGMP manufacturing standards
Exosome Biology & Sourcing
MSC-derived exosome characterization, NTA analysis, cGMP manufacturing standards, and cold-chain logistics for clinic supply.
Synthetic & Analytical Chemistry
Cobalt-catalyzed C-H functionalization, large-scale purification, HPLC validation, and nucleotide process chemistry.
Peptide Formulation
503A/503B compounding regulatory landscape, peptide stability, bioavailability considerations, and practitioner supply chain.
Regenerative Medicine Supply
B2B wholesale distribution of biologics, medical devices, and small molecules to licensed clinical practices nationwide.
DNA Sequencing Chemistry
Nucleotide synthesis and process chemistry for next-generation sequencing reagents and high-throughput analytical platforms.
Compliance & Regulatory
FDA 503A/503B compounding regulations, cGMP standards, and NPI-verified wholesale access framework for medical practices.
Editorial Review Standards
All educational content published on ExaVeyra Sciences is reviewed by Benn Bluestein-Veyra for scientific accuracy, compliance language, and regulatory alignment. The review process covers:
- Molecular biology accuracy for exosome and extracellular vesicle content
- Compliance-forward language avoiding unsubstantiated efficacy claims
- Peer-reviewed citation verification (PubMed, NIH, Nature)
- 503A/503B regulatory accuracy for compounding-related content
- Practitioner-appropriate framing for all clinical application descriptions
What Are Exosomes? A Clinician's Guide
MSC-derived exosome biology, cargo composition, mechanism of action, and clinical research overview.
Exosomes vs PRP: A Clinician's Comparison
Evidence-based comparison of exosome therapy and platelet-rich plasma across clinical applications.
Exosomes in Aesthetic Medicine
Clinical research overview of exosome applications in skin rejuvenation, microneedling, and anti-aging protocols.
Exosome Therapy in Dermatology
Applications of MSC-derived exosomes in dermatological conditions and skin health research.
Exosome Hair Restoration
Research overview of exosome-based approaches to hair loss and scalp health.
503A vs 503B Compounding: What Practitioners Need to Know
Regulatory explainer covering the key differences between 503A and 503B compounding frameworks.
PRP Kit Buying Guide for Clinics
How to evaluate closed-system PRP preparation kits for sports medicine and aesthetic practices.